Olomorasib clinical trials
Also written LY3537982.
How each study uses olomorasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the olomorasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 1
Eli Lilly and Company (14) · Janssen Research & Development, LLC (1) · Daiichi Sankyo (1) · UNC Lineberger Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test olomorasib, phase 3 first.
- Nov 2027A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPhase 3 · Eli Lilly and Company
- Apr 2027Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Phase 1/2 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses olomorasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingPhase 3Eli Lilly and CompanyNCT06119581Written as LY3537982
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingPhase 3Eli Lilly and CompanyNCT06890598Written as Olomorasib
- A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung CancerRecruitingPhase 1/2Janssen Research & Development, LLCNCT07227025Written as Olomorasib
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingPhase 1/2Daiichi SankyoNCT07890714Written as Olomorasib
- A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C MutationNot yet recruitingPhase 2Eli Lilly and CompanyNCT07814417Written as Olomorasib
- A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy ParticipantsRecruitingPhase 1Eli Lilly and CompanyNCT07794592Written as Olomorasib test
- Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLCSuspendedPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07639242Written as Olomorasib
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active, not recruitingPhase 1/2Eli Lilly and CompanyNCT04956640Written as LY3537982
- A Study of LY3537982 in Chinese Participants With Advanced Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT06235983Written as LY3537982
- A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT07044271Written as Olomorasib
- A Study of Olomorasib (LY3537982) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT07439250Written as Olomorasib
- A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney FunctionCompletedPhase 1Eli Lilly and CompanyNCT07137689Written as LY3537982
- A Study of Olomorasib (LY3537982) in Healthy Japanese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT07124013Written as Olomorasib
- A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06719128Written as Olomorasib
- A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06111521Written as LY3537982
- A Study of [14C]-LY3537982 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05901311Written as LY3537982
- A Study of the Effect of Food on LY3537982 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05824858Written as LY3537982
Given beside what is tested · 1 — olomorasib is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]Oct 22, 2026NCT07890714
Codes
What other systems call olomorasib · ClinicalTrials.gg INT016158
- UNII (FDA) C2VJ83PSN7OLOMORASIBConfirmed FDA, Wikidata
- Wikidata Q133445577olomorasibConfirmed FDA, Wikidata
- NCI Thesaurus C181751OlomorasibOne source FDA
- DrugBank DB21697One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C2VJ83PSN7 | OLOMORASIB | Confirmed FDA, Wikidata |
| Wikidata | Q133445577 | olomorasib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C181751 | Olomorasib | One source FDA |
| DrugBank | DB21697 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.